Chemistry:Lufotrelvir
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C24H33N4O9P |
| Molar mass | 552.521 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lufotrelvir (PF-07304814) is an antiviral drug developed by Pfizer which acts as a 3CL protease inhibitor.[1] It is a prodrug with the phosphate group being cleaved in vivo to yield the active agent PF-00835231.[2] Lufotrelvir is in human clinical trials for the treatment of COVID-19, and shows good activity against COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion, and so has been the less favoured candidate for clinical development overall.[3][4][5]
See also
- 3CLpro-1
- Bemnifosbuvir
- Baloxavir marboxil
- Favipiravir
- GC376
- GRL-0617
- Molnupiravir
- Remdesivir
- Ribavirin
- Rupintrivir
- S-217622
- Triazavirin
References
- ↑ "Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19". Journal of Medicinal Chemistry 63 (21): 12725–12747. November 2020. doi:10.1021/acs.jmedchem.0c01063. PMID 33054210.
- ↑ "Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19". Nature Communications 12 (1): 6055. October 2021. doi:10.1038/s41467-021-26239-2. PMID 34663813. Bibcode: 2021NatCo..12.6055B.
- ↑ "A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19". Journal of Virology 95 (7). March 2021. doi:10.1128/JVI.01819-20. PMID 33622961.
- ↑ "Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study". Molecules 26 (6): 1678. March 2021. doi:10.3390/molecules26061678. PMID 33802860.
- ↑ "Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection". Current Opinion in Virology 49: 36–40. August 2021. doi:10.1016/j.coviro.2021.04.006. PMID 34029993.
 |  |
